Posterior Reversible Encephalopathy Syndrome Associated With Dose-adjusted EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) Chemotherapy

Conclusion To the best of our knowledge, the present study is the first description of PRES associated with DA-EPOCH. The key risk factors for the development of PRES identified in our study included hypertension, fluid imbalance, electrolyte abnormalities, baseline organ dysfunction, a high tumor burden, and the presence of pre-existing CNS insults during chemotherapy, such as CNS infection. Patients with these risk factors appear to have a greater risk of developing PRES and should be monitored closely during treatment. Micro-Abstract The purpose of our study was to identify risk factors for the development of posterior reversible encephalopathy syndrome (PRES) after administration of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (DA-EPOCH). Of 44 patients receiving DA-EPOCH at our institution, 3 (7%) developed PRES. The patients who developed PRES were more likely to have a pre-existing central nervous system insult, fluid status or electrolytes abnormalities, and hypertension.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research